findmyKOL
Clinical trialNCT06529406RecruitingPhase 4Interventional

Prospective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod

SponsorUniversity of Colorado, DenverEnrollment100Relapsing Multiple Sclerosis
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • University of Colorado Anschutz Medical Campus

    Aurora, Colorado, United States

    Recruiting
  • Cleveland Clinic

    Las Vegas, Nevada, United States

    Carrie M Hersh, DO
    Recruiting
  • Cleveland Clinic

    Cleveland, Ohio, United States

    Devon S Conway, MD
    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
29 Jul 2024
Primary completion
1 Aug 2028
Completion
1 Aug 2029
Last update posted
18 Sept 2025
Registered enrollment
100
Registry id
NCT06529406
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.